Vivos Therapeutics, Inc. (VVOS), a medical device and technology company, announced on Thursday that it has inked a deal with institutional investors to sell 1.363 million shares at $3.15 per share in a registered direct offering.
The gross proceeds from the offering are expected to be around $4.3 million. The company intends to use the net proceeds for working capital and general corporate purposes.
The offering anticipated to be closed on or about September 20.
VVOS was trading down by 23 percent at $3.180 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.